Applies to Employer and ACA Marketplace plans.
Covered with requirementsQualification pathways
You can qualify through any one of these.
New T2DM diagnosis (diagnosed ≤ 2 years ago)
All of:
- Submission of medical records (e.g., chart notes) confirming diagnosis of type 2 diabetes mellitus
Plus any one of:
- A1C ≥ 6.5%
- Fasting plasma glucose (FPG) ≥ 126 mg/dL
- 2-hour plasma glucose ≥ 200 mg/dL during oral glucose tolerance test
- Random plasma glucose ≥ 200 mg/dL in patient with classic symptoms of hyperglycemia or hyperglycemic crisis
Ongoing T2DM treatment (diagnosed > 2 years ago)
All of:
- Submission of medical records (e.g., chart notes) confirming diagnosis of type 2 diabetes mellitus
- Patient diagnosed greater than 2 years ago
Documentation to bring
- Medical records (e.g., chart notes) confirming diagnosis of type 2 diabetes mellitus
- For new diagnosis (≤2 years): at least one qualifying lab value (A1C ≥ 6.5%, FPG ≥ 126 mg/dL, 2-hr PG ≥ 200 mg/dL on OGTT, or random PG ≥ 200 mg/dL with classic hyperglycemia symptoms)
- For ongoing treatment (>2 years): chart notes confirming T2DM diagnosis
Approval and renewal
- Initial approval: 12 months
- Renewal: every 12 months
- Renewal: Re-authorization may be based solely on previous claim/medication history, diagnosis codes (ICD-10), and/or claim logic via automated processes.
Not covered when
- Not approved for weight loss; use solely for weight loss is not covered
- Type 1 diabetes
Policy note: Mounjaro is described as a GIP/GLP-1 dual receptor agonist. The policy explicitly states these medications are not FDA approved for weight loss and that medications used for weight loss are typically excluded from benefit coverage. Adult-only indication per FDA label and per document background. Automated approval/re-approval processes may apply based on claim/medication history and ICD-10 codes. Supply limits may be in place.
Policy effective July 1, 2025 · verified June 2, 2026 · source: PA Notification Diabetes Agents GLP-1 Receptor Agonists